About Auriga partners
Auriga Partners: Supporting Software and Life Sciences Entrepreneurs for Over 20 Years
Auriga Partners is a leading venture capital firm that has been supporting software and life sciences entrepreneurs for more than 20 years. The company has a proven track record of returning world-class performances through countless trade-sales and IPOs. With its deep expertise in the technology and healthcare sectors, Auriga Partners is committed to helping innovative startups grow into successful businesses.
Founded in 1998, Auriga Partners has become one of the most respected venture capital firms in Europe. The company's mission is to identify promising startups with disruptive technologies or business models, provide them with the necessary funding and support, and help them achieve their full potential. Over the years, Auriga Partners has invested in more than 100 companies across Europe and North America.
One of the key strengths of Auriga Partners is its team of experienced professionals who have a deep understanding of both technology and healthcare industries. The team includes seasoned investors, entrepreneurs, scientists, engineers, lawyers, and other experts who work closely with portfolio companies to help them overcome challenges and seize opportunities.
Auriga Partner's investment strategy focuses on early-stage companies that have strong intellectual property positions or unique market positions. The firm typically invests between €1 million to €10 million per round in seed-stage or Series A financing rounds. In addition to providing funding, Auriga Partners also offers strategic guidance on product development, market positioning, fundraising strategies as well as access to its extensive network of industry contacts.
The company's portfolio includes some of the most innovative startups in software development such as Algolia (a search-as-a-service platform), Mirakl (an online marketplace platform), Scality (a distributed file system provider) among others; as well as life sciences such as Erytech Pharma (a biopharmaceutical company developing therapies for rare diseases), Pixium Vision (a medical device company developing bionic vision systems), and Stentys (a medical device company developing stents for the treatment of coronary artery disease).
Auriga Partners has a strong track record of successful exits, with more than 50 trade-sales and IPOs to date. Some of the notable exits include the sale of Netcentric to Adobe, the sale of Biovex to Amgen, and the IPOs of Pixium Vision and Erytech Pharma. These successes have not only generated significant returns for Auriga Partners' investors but also helped create jobs, drive innovation, and improve people's lives.
In addition to its investment activities, Auriga Partners is also actively involved in promoting entrepreneurship and innovation in Europe. The company organizes events such as "Startup Tour" which brings together entrepreneurs, investors, corporates as well as public institutions across Europe; it also supports initiatives such as "La French Tech" which aims at promoting French startups globally.
In conclusion, Auriga Partners is a leading venture capital firm that has been supporting software and life sciences entrepreneurs for over 20 years. With its deep expertise in technology and healthcare sectors combined with its experienced team of professionals who work closely with portfolio companies; Auriga Partners is committed to helping innovative startups grow into successful businesses. Its proven track record of successful exits demonstrates its ability to identify promising startups early on and help them achieve their full potential.